Aim Dyslipidemia is a key risk factor for atherosclerosis, which is strongly related to coronary artery disease （CAD）. The aim of the present study was to investigate the effects of Hedan on serum lipid profile, proprotein convertase subtilisin/Kexin 9 （PSCK9） and high density lipoprotein （HDL） subfractions in patients with hyperlipidemia. Methods Thirty-seven patients with hyperlipidemia were randomized to treatment with Hedan tablet 4.38 g/day as Hedan group （n＝18） and placebo （n＝19） as control group for 8 weeks. The lipid profile, PCSK9 and HDL subfractions were determined at day 0 and week 8 in both groups respectively. Results Hedan treatment for 8 weeks mildly decreased serum low density lipoprotein cholesterol （LDLC） levels, while no changes were found in total cholesterol （TC）, triglyceride （TG） and PCSK9 concentrations. Furthermore, Hedan treatment increased the concentration of large high density lipoprotein cholesterol （HDLC） and the percentage of large HDL subfraction, while decreased the concentration of small HDLC and the percentage of small HDL subfraction without changing serum HDLC levels in patients with hyperlipidemia. Conclusion The results suggested that Hedan treatment of 4.38 g/d for 8 weeks could confer a favorable effect on serum LDLC concentration as well as HDL subfractions.